Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]
News [3530]
Articles [90]
Editorials [5]
Conferences [156]
elearning [19]
Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers
Dr Sibylle Loibl - German Breast Cancer Group
Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers ( Dr Sibylle Loibl - German Breast Cancer Group )
26 Oct 2016
Coming of age for CDK 4/6 inhibitors: Interactive session and close
Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy
Coming of age for CDK 4/6 inhibitors: Interactive session and close ( Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy )
26 Oct 2016
Biomarkers of sensitivity and resistance
Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Biomarkers of sensitivity and resistance ( Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
26 Oct 2016
Editor's ESMO 2016 roundup
Prof Gordon McVie - Editor in Chief, ecancer
Editor's ESMO 2016 roundup ( Prof Gordon McVie - Editor in Chief, ecancer )
24 Oct 2016
PDL-1 assay concordance
Dr Jill Walker - AstraZeneca, UK
PDL-1 assay concordance ( Dr Jill Walker - AstraZeneca, UK )
20 Oct 2016
CDK4/6 inhibition: PALOMA2 versus MONALEESA2
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria
CDK4/6 inhibition: PALOMA2 versus MONALEESA2 ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )
17 Oct 2016
First evidence of significant clinical activity of PD1 inhibition in metastatic...
Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University...
First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer ( Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University, Portland, USA )
17 Oct 2016
ESMO 2016 conference highlights
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
ESMO 2016 conference highlights ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1...
Dr Omid Hamid - The Angeles Clinic, California, USA
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: ( Dr Omid Hamid - The Angeles Clinic, California, USA )
12 Oct 2016
ESMO 2016 prostate cancer highlights
Dr Eleni Efstathiou, Prof Karim Fizazi, Dr Chris Parker
ESMO 2016 prostate cancer highlights ( Dr Eleni Efstathiou, Prof Karim Fizazi, Dr Chris Parker )
10 Oct 2016
Oncolytic virotherapy using coxsackie virus
Dr Hardev Pandha - University of Surrey, Guildford, UK
Oncolytic virotherapy using coxsackie virus ( Dr Hardev Pandha - University of Surrey, Guildford, UK )
10 Oct 2016
Results of the Activ8 trial of novel immunotherapy motolimod
Dr Ezra Cohen - UC San Diego, San Diego, USA
Results of the Activ8 trial of novel immunotherapy motolimod ( Dr Ezra Cohen - UC San Diego, San Diego, USA )
10 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation